Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes

Fig. 3

Probability of events of pancreatic outcomes with incretin-based agents versus placebo. Effect of incretin-based agents on acute pancreatitis (a) and pancreatic cancer (b) was analyzed individually. CI confidential interval, DPP-4I dipeptidyl peptidase-4 inhibitor, GLP-1A glucagon-like peptide-1 agonist

Back to article page